AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02025166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Pain treatment with aniline analgesics (paracetamol) at the time of the procedure
Study NCT02025166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lornoxicam
Description: Pain treatment with NSAID (lornoxicam) at the time of the procedure
Study NCT00072631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva (Trademark) (erlotinib HCl, OSI-774)
Description: Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
Study NCT03719820 — intervention group
Intervention type: DRUG
Intervention: aggressive medical management
Description: Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
Study NCT03845543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminor-14 Paclitaxel eluting balloon
Description: Patients will be treated with the Luminor-14 paclitaxel eluting balloon
Study NCT04214873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 Laser System
Description: PiQo4 Laser System for treatment of POH
Study NCT00571610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Description: Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A $10 Survey Incentive
Description: Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A $20 Survey Incentive
Description: Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emphasis of Government Involvement
Description: Individuals see a message emphasizing the involvement of the government in the study,
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emphasis of Academic Researchers Involvement
Description: Individuals see a message emphasizing the involvement of academic researchers in the study,
Study NCT03381794 — intervention group
Intervention type: PROCEDURE
Intervention: Corneal transplantation
Description: PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
Study NCT00845923 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Civamide Patch
Description: Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
Study NCT03997968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851
Description: Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cost-Benefit Frame
Description: Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duty Frame
Description: Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racial/Ethnic Frame
Description: Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
Study NCT04568889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Messaging
Description: Individuals will see no messaging in the baseline survey.
Study NCT03768661 — intervention group
Intervention type: PROCEDURE
Intervention: Single-incision Laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision
Study NCT03768661 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: laparoscopic cholecystectomy performed using three-trocars standard technique
Study NCT02985697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The intervention being tested is intranasal dexmedetomidine
Study NCT02985697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
Study NCT02985697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hydrochloride
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
Study NCT02985697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.
Study NCT02985697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.
Study NCT04902742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided ganglion impar block
Description: Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
Study NCT04902742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided caudal epidural steroid injection
Description: Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
Study NCT03746275 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (BAY59-7939, Xarelto)
Description: 2.5 mg twice daily
Study NCT03746275 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic acid
Description: 75 - 100 mg once daily according to local label
Study NCT03863717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm Endurance Exercise Training
Description: Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
Study NCT03863717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
Study NCT03968887 — intervention group
Intervention type: OTHER
Intervention: plasma oxidized low-density lipoprotein levels
Description: Detection of plasma oxidized low-density lipoprotein levels
Study NCT00514423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation by professonals
Study NCT00514423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation by peer-moderators
Study NCT00514423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-education
Study NCT00514423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Noneducational video group (control group)
Study NCT01038193 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
Study NCT02193581 — intervention group
Intervention type: DEVICE
Intervention: MDS
Description: Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
Study NCT03577873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gallbladder preserved
Description: Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
Study NCT03577873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
Study NCT00805948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Talent Thoracic Stent Graft System
Description: endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
Study NCT03296579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
Study NCT03296579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: The patient breathes against a constant pressure delivered by face mask.
Study NCT03296579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium
Description: Nebulized q6h
Study NCT01006967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard program of physical therapy for gait and balance
Study NCT03111667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Marijuana Check Up
Description: Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
Study NCT03111667 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Referral to community resources
Study NCT03111667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Coaching
Description: Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
Study NCT03111667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: As Needed Coaching
Description: As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
Study NCT01072799 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses (Day 1 and Day 22); 0.5mL
Study NCT01072799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H1N1 2009 Influenza VLP Vaccine
Description: Two doses (Day 1 \& Day 22); 0.5mL
Study NCT03296579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 50mg/kg IV, 4 doses q6h
Study NCT03296579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: 6mg/kg IV (if no progress)
Study NCT03296579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard steroid dose, hourly salbutamol, oxygen as needed
Description: Standard common therapies for all three arms.
Study NCT03296579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard steroid dose, hourly salbutamol, oxygen as needed
Description: Standard common therapies for all three arms.
Study NCT04320264 — intervention group
Intervention type: PROCEDURE
Intervention: Weight loss surgery
Description: Severely obese women (BMI >40) undergo sleeve gastrectomy
Study NCT02552550 — intervention group
Intervention type: PROCEDURE
Intervention: Ability to swallow, speak and quality of life
Description: This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
Study NCT03293862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prophylactic polypropilene mesh
Description: Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
Study NCT03293862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midline Fascial Closure
Description: midline fascial closure using uninterrupted PDS 0 suture
Study NCT03293862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline Fascial Closure
Description: midline fascial closure using uninterrupted PDS 0 suture
Study NCT03293862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vacuum drainage system
Description: Placement of a subcutaneous vacuum drainage system
Study NCT03412838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: graft surgery
Description: A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
Study NCT01400100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial application of Octreotide
Description: 500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
Study NCT01400100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile NaCl (sodium chloride) 0,9% solution
Description: a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
Study NCT04609293 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: camrelizumab+apatinib+hyperfractionated radiotherapy
Description: Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
Study NCT00536588 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SCH 721015 with SCH 209702
Description: Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
Study NCT02251509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT02251509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Study NCT01910831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DerMend Moisturizing Bruise Formula
Description: DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
Study NCT01910831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-active placebo control
Description: Non-active placebo control
Study NCT00288769 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: daily sublingual tablets Vitamin B12 1000 mcg versus placebo
Study NCT04747184 — intervention group
Intervention type: OTHER
Intervention: DNA extraction and 16S rRNA sequencing
Description: DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
Study NCT02583308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tubes not allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
Study NCT02583308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
Study NCT02527330 — intervention group
Intervention type: OTHER
Intervention: MR T2* imaging
Description: Cardiac magnetic resonance imaging with T2\* imaging
Study NCT01195155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
Study NCT01195155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
Study NCT01195155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
Study NCT02007161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac potassium 50 mg
Description: Diclofenac potassium 50 mg
Study NCT01117662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
Study NCT01117662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous application of placebo (NaCl 0,9 %) matching active treatment
Study NCT03527979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: IVF/ICSI
Study NCT00569075 — intervention group
Intervention type: OTHER
Intervention: collection of gingival crevicular fluid
Description: GCF samples will be collected at 3 month intervals
Study NCT02019173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boot Camp Balance Training
Description: Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
Study NCT04179084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: 5mg qd, 2weeks on, 1week off
Study NCT04179084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg q3w
Study NCT02150993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + Emtricitabine or Lamivudine + Zidovudine
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
Study NCT02150993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
Study NCT02150993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + Emtricitabine or Lamivudine + Raltegravir
Description: TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
Study NCT03221335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided RFA
Description: All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
Study NCT02320552 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT02312128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: DASH Score, PRWE Score, Mayo Wrist Score
Study NCT02312128 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X- Ray
Description: X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
Study NCT01027767 — intervention group
Intervention type: DEVICE
Intervention: Molecular Breast Imaging
Description: Molecular Breast Imaging
Study NCT02312128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grip Strength
Description: Grip strength measurement
Study NCT02312128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAS Score
Description: Measurement pain according to the visual analogue scale (VAS)
Study NCT02312128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of Motion measurement
Description: Angle measurement of the active range of motion in the wrist